CCCC - C4 Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Watertown,
United States
Type: Equity
CCCC price evolution
CCCC
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $130.03 | $64.42 | $48.16 | $52.76 |
| Short term investments | $127.09 | $155.6 | $222.4 | $220.85 |
| Net receivables | $11.8 | $0.5 | $1.03 | $0.53 |
| Inventory | ||||
| Total current assets | $271.19 | $223.69 | $274.39 | $278.45 |
| Long term investments | $28.01 | $29.86 | $19.41 | $34.71 |
| Property, plant & equipment | $71.09 | $72.81 | $74.64 | $76.24 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $105.26 | $109.33 | $100.62 | $117.58 |
| Total investments | $155.1 | $185.46 | $241.82 | $255.56 |
| Total assets | $376.45 | $333.01 | $375.01 | $396.04 |
| Current liabilities | ||||
| Accounts payable | $1.45 | $1.28 | $2.25 | $1.03 |
| Deferred revenue | $37.28 | $28.05 | $38.62 | $30.78 |
| Short long term debt | $5.22 | $5.09 | $15.29 | $7.11 |
| Total current liabilities | $42.77 | $30.27 | $48.24 | $39.38 |
| Long term debt | $65.76 | $67.09 | $68.42 | $78.34 |
| Total noncurrent liabilities | $87.57 | $86.72 | $93.06 | $94.19 |
| Total debt | $70.98 | $72.18 | $83.71 | $85.45 |
| Total liabilities | $130.34 | $116.99 | $141.3 | $133.57 |
| Shareholders' equity | ||||
| Retained earnings | -$528.38 | -$493.63 | -$466.59 | -$430.67 |
| Other shareholder equity | -$0.13 | -$0.9 | -$1.77 | -$2.47 |
| Total shareholder equity | $246.11 | $216.02 | $233.71 | $262.47 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $130.03 | $33.03 | $79.4 | $184.3 |
| Short term investments | $127.09 | $246.4 | $233.16 | $189.96 |
| Net receivables | $11.8 | $1.47 | $5.72 | $4.48 |
| Inventory | ||||
| Total current assets | $271.19 | $287.56 | $325.69 | $381.01 |
| Long term investments | $28.01 | $60.96 | $142.2 | |
| Property, plant & equipment | $71.09 | $77.52 | $35.05 | $16.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $105.26 | $143.28 | $181.08 | $19.13 |
| Total investments | $155.1 | $307.36 | $375.36 | $189.96 |
| Total assets | $376.45 | $430.84 | $506.76 | $400.14 |
| Current liabilities | ||||
| Accounts payable | $1.45 | $1.17 | $4.51 | $5.68 |
| Deferred revenue | $37.28 | $33.51 | $56.17 | $81.22 |
| Short long term debt | $5.22 | $6.99 | $1.33 | $1.04 |
| Total current liabilities | $42.77 | $44.55 | $51.25 | $43.85 |
| Long term debt | $65.76 | $9.2 | $41.55 | $21.88 |
| Total noncurrent liabilities | $87.57 | $97.06 | $65.91 | $75.5 |
| Total debt | $70.98 | $87.15 | $42.88 | $22.92 |
| Total liabilities | $130.34 | $141.61 | $117.16 | $119.35 |
| Shareholders' equity | ||||
| Retained earnings | -$528.38 | -$395.89 | -$267.71 | -$183.82 |
| Other shareholder equity | -$0.13 | -$4.14 | -$0.78 | $0.01 |
| Total shareholder equity | $246.11 | $289.23 | $389.61 | $280.79 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.26 | $11.07 | $2.66 | $3.76 |
| Cost of revenue | ||||
| Gross Profit | $3.26 | $11.07 | $2.66 | $3.76 |
| Operating activities | ||||
| Research & development | $30.39 | $28.35 | $29.93 | $29.04 |
| Selling, general & administrative | $10.3 | $10.53 | $10.31 | $10.95 |
| Total operating expenses | $40.69 | $38.88 | $40.23 | $39.99 |
| Operating income | -$37.43 | -$27.81 | -$37.57 | -$36.23 |
| Income from continuing operations | ||||
| EBIT | -$34.48 | -$25.87 | -$35.32 | -$34.17 |
| Income tax expense | $0.28 | $1 | ||
| Interest expense | $0.17 | $0.6 | $0.61 | |
| Net income | ||||
| Net income | -$34.75 | -$27.04 | -$35.92 | -$34.78 |
| Income (for common shares) | -$34.75 | -$27.04 | -$35.92 | -$34.78 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $20.76 | $31.1 | $45.78 | $33.2 |
| Cost of revenue | ||||
| Gross Profit | $20.76 | $31.1 | $45.78 | $33.2 |
| Operating activities | ||||
| Research & development | $117.71 | $117.84 | $94.67 | $78.44 |
| Selling, general & administrative | $42.08 | $42.79 | $33.25 | $15.2 |
| Total operating expenses | $159.79 | $160.63 | $127.92 | $93.64 |
| Operating income | -$139.03 | -$129.53 | -$82.13 | -$60.45 |
| Income from continuing operations | ||||
| EBIT | -$129.84 | -$125.96 | -$81.75 | -$65.73 |
| Income tax expense | $1.28 | -$0.63 | ||
| Interest expense | $1.37 | $2.22 | $2.15 | $1.23 |
| Net income | ||||
| Net income | -$132.49 | -$128.18 | -$83.89 | -$66.33 |
| Income (for common shares) | -$132.49 | -$128.18 | -$83.89 | -$66.33 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$34.75 | -$27.04 | -$35.92 | -$34.78 |
| Operating activities | ||||
| Depreciation | $1.99 | $2 | $1.99 | $2.06 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.36 | $8.2 | $6.42 | $6.25 |
| Total cash flows from operations | -$24.01 | -$30.71 | -$19 | -$33.13 |
| Investing activities | ||||
| Capital expenditures | -$0.16 | -$0.6 | -$0.36 | -$0.59 |
| Investments | $32.1 | $58.33 | $15.51 | $54.12 |
| Total cash flows from investing | $31.95 | $57.73 | $15.15 | $53.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $57.67 | -$0.02 | $0 | -$0.04 |
| Net borrowings | -$11 | -$0.75 | -$0.75 | |
| Total cash flows from financing | $57.67 | -$10.75 | -$0.75 | -$0.68 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $65.61 | $16.27 | -$4.59 | $19.72 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$132.49 | -$128.18 | -$83.89 | -$66.33 |
| Operating activities | ||||
| Depreciation | $8.04 | $7.57 | $1.49 | $2.84 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $27.23 | $30.02 | $21.51 | $3.43 |
| Total cash flows from operations | -$106.84 | -$105.94 | -$86.97 | -$67.25 |
| Investing activities | ||||
| Capital expenditures | -$1.71 | -$5.5 | -$1.28 | -$0.65 |
| Investments | $160.06 | $63.92 | -$188.06 | -$189.85 |
| Total cash flows from investing | $158.35 | $58.42 | -$189.34 | -$190.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $57.62 | $0.78 | $171.51 | $192.16 |
| Net borrowings | -$12.5 | $11.97 | ||
| Total cash flows from financing | $45.49 | $1.15 | $171.4 | $348.93 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $97 | -$46.37 | -$104.9 | $91.18 |
News
Fundamentals
| Market cap | $391.22M |
|---|---|
| Enterprise value | $332.17M |
| Shares outstanding | 60.47M |
| Revenue | $20.76M |
|---|---|
| EBITDA | -$121.80M |
| EBIT | -$129.84M |
| Net Income | -$132.49M |
| Revenue Q/Q | 14.26% |
| Revenue Y/Y | -33.25% |
| P/E ratio | -2.95 |
|---|---|
| EV/Sales | 16.00 |
| EV/EBITDA | -2.73 |
| EV/EBIT | -2.56 |
| P/S ratio | 18.85 |
| P/B ratio | 1.59 |
| Book/Share | 4.07 |
| Cash/Share | 2.15 |
| EPS | -$2.19 |
|---|---|
| ROA | -35.80% |
| ROE | -55.30% |
| Debt/Equity | 0.53 |
|---|---|
| Net debt/EBITDA | -0.00 |
| Current ratio | 6.34 |
| Quick ratio | 6.34 |